CV
ABBV icon

Counterweight Ventures’s AbbVie ABBV Stock Holding History

Counterweight Ventures’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.69M Sell
18,646
-779
-4% -$168K 2.34% 14
2026
Q1 		$4.22M Buy
19,425
+1,016
+6% +$225K 2.37% 12
2025
Q4 		$4.21M Sell
18,409
-35
-0.2% -$7.97K 2.36% 14
2025
Q3 		$4.27M Sell
18,444
-2,470
-12% -$503K 2.5% 14
2025
Q2 		$3.88M Buy
20,914
+603
+3% +$112K 2.54% 16
2025
Q1 		$4.26M Buy
20,311
+40
+0.2% +$7.78K 3.05% 8
2024
Q4 		$3.6M Buy
20,271
+675
+3% +$124K 2.55% 16
2024
Q3 		$3.87M Buy
19,596
+3,148
+19% +$588K 2.74% 11
2024
Q2 		$2.82M Buy
16,448
+96
+0.6% +$15.9K 2.13% 18
2024
Q1 		$2.98M Buy
16,352
+539
+3% +$92.9K 2.4% 14
2023
Q4 		$2.45M Buy
+15,813
New +$2.31M 2.23% 18

Other funds holding ABBV

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Counterweight Ventures's ABBV Position: Q2 2026 in Review

Counterweight Ventures reduced its AbbVie (ABBV) stake by 4% in Q2 2026, selling an estimated $168K and leaving 18,646 shares worth $4.69M. The position accounts for 2.34% of the portfolio, ranked #14.

Counterweight Ventures first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Counterweight Ventures held 18,646 shares of AbbVie worth $4.69M as of Q2 2026.
  • Counterweight Ventures sold 779 AbbVie shares in Q2 2026, an estimated $168K.
  • AbbVie made up 2.34% of Counterweight Ventures's portfolio in Q2 2026, its #14 holding.
  • Counterweight Ventures first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Counterweight Ventures's 13F filing for Q2 2026, filed 23 Jul 2026.